Question

Is stem cell therapy for Intellectual Disability FDA-approved?

No generic stem-cell or exosome product is FDA-approved to treat intellectual disability. A trial listing, hospital credential or product described as neural does not constitute approval for a developmental indication.

Medical review statusPending clinical sign-offLast evidence update: 2026-08-05Methodology and editorial standards
Clinical review team: Dr Kamelia Milcheva, Hematologist · Dr Vadym Uvarov, Board-Certified Physician · Hepatobiliary Surgeon · Candidate of Medical SciencesEditorial responsibility: StemCellAtlas research teamEducational information only. This page does not provide medical advice, diagnosis or a treatment recommendation.

How stem cells are studied for Intellectual Disability

Intellectual disability is the current clinical term; the older label retained in this source slug is outdated and should not appear in patient-facing text. Intellectual disability has many genetic, prenatal, perinatal, metabolic and acquired causes and is defined through intellectual and adaptive functioning. A generic cell infusion cannot be assumed to address those different causes or reverse established developmental differences.

Am I a candidate? → · Intellectual Disability: full overview → · Intellectual Disability cost → · Cost →

Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.

Sources & further reading

Explore all sections · Data & downloads

Compare cell-therapy evidence, registered studies and published price observations.

StemCellAtlas is a source-first research and cost-planning guide. It separates registry and regulator evidence from heterogeneous commercial observations.

Request written information